We are proud to announce new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial. The results, which will be presented at the #ASTRO26 Annual Meeting (Abstract #312), demonstrate that the Decipher® Prostate Genomic Classifier can predict which patients are more likely to benefit from adding short-term androgen deprivation therapy (ADT) to dose-escalated radiation, providing Level 1B* prognostic and predictive evidence. | Impact | The findings provide the first evidence that Decipher testing can predict hormone therapy benefit in intermediate-risk prostate cancer, extending its long-established role in assessing the risk of prostate cancer progression to informing treatment selection for patients with intermediate-risk disease. While ADT can reduce the risk of recurrence and distant spread, it can also have metabolic and quality-of-life effects. Because intermediate-risk disease is biologically diverse, clinical variables such as Gleason grade, prostate-specific antigen (PSA) or clinical stage alone may not reveal which patients are most likely to benefit from adding the therapy. The NRG/RTOG 0815 trial analysis helps move #DecipherProstate testing closer to answering  a consequential question in prostate cancer care: Will hormonal therapy make a meaningful difference for this patient? Study author, Angela Jia, M.D., Ph.D. will present the results. | Presentation Details | 📅 Date: Tuesday, September 29 ⏰ Time: 3:55pm – 4:05pm ET 📍 Location: Room 210 *Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101, 1446–1452 (2009). doi.org/10.1093/jnci/djp335 | Resources| 📄 Read full press release - investor.veracyte.com/news-r… 🔗 Event information - veracyte.com/company/event/a… #RadOnc #PrecisionOncology #ClinicalTrials #RealWorldData #TeamVeracyte This article contains forward-looking statements. These forward-looking statements involve risks and uncertainties. Please visit our website for more information: veracyte.com/legal/cautionar…

#TeamVeracyte is in Boston September 26–30 for the American Society for Radiation Oncology Annual Meeting (#ASTRO26)! Stop by Booth 1548 to learn how Veracyte is informing clinical decision-making and advancing research in #RadiationOncology through genomic insights in #ProstateCancer. Ask about: 🔹 Decipher® Prostate Genomic Classifier: a test that supports prostate cancer care decision-making, helping clinicians and their patients navigate treatment choices with clarity 🔹 Decipher GRID (Genomic Resource for Intelligent Discovery): a proprietary research-use-only database designed to help advance understanding of urologic cancers at the molecular level | Resources | 🔗 Event details and full presentation schedule - veracyte.com/company/event/a… 📄 Decipher Prostate test - veracyte.com/tests/decipher-… 📄 Decipher GRID data resource - veracyte.com/innovation/deci… #RadOnc #PrecisionOncology #DecipherProstate #DecipherGRID #DecipherUrologicCancers